2021
The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.
Lee N, Sherman E, Schöder H, McBride S, Yu Y, Kang J, Tsai C, Gelblum D, Boyle J, Singh B, Cohen M, Cracchiolo J, Ganly I, Dunn L, Kriplani A, Fetten J, Michel L, Wong R, Pfister D, Riaz N. The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer. Journal Of Clinical Oncology 2021, 39: 6019-6019. DOI: 10.1200/jco.2021.39.15_suppl.6019.Peer-Reviewed Original ResearchPositron emission tomographyGrade 1Locoregional controlNodal diseaseOropharyngeal carcinomaOPC patientsGrade 2Primary siteGrade 3 adverse eventsWeight lossDe-escalated patientsGross nodal diseaseRecurrent nodal diseaseResolution of hypoxiaSuccessful salvage surgeryExcellent locoregional controlOverall survival rateSpecific treatment responsesPatient-specific treatment responsesConcurrent chemotherapyDefinitive doseMucositis ratesAdditional therapySalvage surgeryAdverse events
2020
Outcomes and toxicities of definitive radiotherapy and reirradiation using 3‐dimensional conformal or intensity‐modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies
Fan M, Kang JJ, Lee A, Fan D, Wang H, Kitpanit S, Fox P, Sine K, Mah D, McBride SM, Tsai CJ, Riaz N, Dunn LA, Sherman EJ, Michel L, Singh B, Ganly I, Wong RJ, Boyle JO, Cohen MA, Lee NY. Outcomes and toxicities of definitive radiotherapy and reirradiation using 3‐dimensional conformal or intensity‐modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. Cancer 2020, 126: 1905-1916. PMID: 32097507, PMCID: PMC7304541, DOI: 10.1002/cncr.32776.Peer-Reviewed Original ResearchConceptsGrade 3 toxicityRadiation-naive patientsIntensity-modulated proton therapyLate grade 3 toxicityParanasal sinus cancerLocal controlNasal cavitySinus cancerAcute grade 3 toxicityGray relative biological effectivenessProton therapyMore grade 1Paranasal sinus malignanciesRemarkable local controlDisease-free survivalInferior local controlOverall survival rateDefinitive radiotherapyConsecutive patientsSinus malignanciesMedian dosesHigher complicationsDistant controlTherapeutic ratioPatients